A blog about chemistry, drug development, science, and technology
I read today that Genentech expects to get 15 new treatments approved for a variety of diseases by 2010. I can only say I will be greatly impressed if hey can indeed pull this off. Genentech currently has 12 products on the market with Avastin being their biggest seller ($1.1 billion in 2005). From the article and other places I’ve read about it, it is unclear how many specific drugs they are talking about. It appears that they are counting the number of indications rather than the number of new biological entities. So say a new drug is used for 3 different indications, that would count as 3 towards that total. They do have about 20 potential drugs at various stages of development but given the odds in the drug development process, I wouldn’t count on all of them getting through their trials.
In the interest of full disclosure, I do own a few shares of Genentech stock. While I really hope this is the case, I’m being cautiously optimistic.
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 1.147 seconds